Research Topics
Species | Y L KasamonSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Management of symptomatic, untreated chronic lymphocytic leukemiaYvette L Kasamon
Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Blood Rev 21:143-56. 2007..Examples of possible treatment algorithms based on risk category are explored. How to tailor treatment based on these newer prognostic factors remains a central, as yet unanswered management question...- Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemiaYvette L Kasamon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Clin Cancer Res 11:8413-7. 2005.... 
FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphomaYvette L Kasamon
Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
Curr Opin Oncol 20:206-19. 2008..Outcomes based on midtreatment FDG PET performed during primary and salvage therapy are reviewed and management strategies considered, with a focus on treatment intensification for poor-risk disease as identified by metabolic imaging...
Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomasYvette L Kasamon
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 17:365-73. 2011..Thus, 4-HC-purged ABMT can produce extended remissions in a subgroup of patients with indolent lymphomas...- Immunotherapies for Hodgkin's lymphomaYvette L Kasamon
Division of Hematologic Malignancies, Johns Hopkins Medical Institutions, Baltimore, MD, USA
Crit Rev Oncol Hematol 66:135-44. 2008..The clinical experience with adoptive immunotherapy of Epstein-Barr virus positive tumors, and with monoclonal antibodies directed against CD30, CD20, and other antigens, is herein reviewed... - Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanningYvette L Kasamon
Johns Hopkins University, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 15:242-8. 2009..The favorable outcome achieved here in historically poor-risk patients warrants further, more definitive investigation of treatment modification based on early PET scanning... - Blood or marrow transplantation for mantle cell lymphomaYvette L Kasamon
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Curr Opin Oncol 19:128-35. 2007..Mantle cell lymphoma is a generally incurable disease for which blood or marrow transplantation is frequently considered. This review assesses the more recent literature on high-dose therapeutic approaches for mantle cell lymphoma... - Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphomaY L Kasamon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Ann Oncol 21:1203-10. 2010..Rituximab may improve transplant outcomes but may delay immunologic recovery... - Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeYvette L Kasamon
Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 16:482-9. 2010..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide... - Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimenJ Bolanos-Meade
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Bone Marrow Transplant 43:477-80. 2009..The combination of fludarabine and alemtuzumab is an effective and well-tolerated salvage conditioning regimen for patients who experience graft failure after blood or marrow transplants... - High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvementYvette L Kasamon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 11:93-100. 2005..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated... - Circulating clonotypic B cells in classic Hodgkin lymphomaRichard J Jones
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Blood 113:5920-6. 2009..Although the clinical significance of circulating clonotypic B cells in HL remains unclear, these data suggest they may be the initiating cells for HL... - K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylateB Douglas Smith
Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and St Agnes Hospital, Baltimore, Maryland 21231, USA
Clin Cancer Res 16:338-47. 2010..A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia... - Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade
George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Biol Blood Marrow Transplant 13:1185-91. 2007..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts... - FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategyYvette L Kasamon
Divisions of Hematologic Malignancies and Nuclear Medicine, Johns Hopkins Medical Institutions, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 207, Baltimore, MD 21231, USA
Curr Opin Oncol 16:100-5. 2004..Early identification of high-risk patients through the combination of positron emission tomography and existing prognostic indices could lead to earlier implementation of intensive therapies and improved clinical outcomes... - Integrating PET and PET/CT into the risk-adapted therapy of lymphomaYvette L Kasamon
Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Nucl Med 48:19S-27S. 2007..We selected aggressive lymphomas as a platform for the discussion of these imaging modalities in oncology patients and the resulting management questions... - Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphomaYvette L Kasamon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Biol Blood Marrow Transplant 11:39-46. 2005..Whether allogeneic BMT ultimately confers an advantage because of a graft-versus-lymphoma effect remains to be determined... - MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinomaTomohide Tatsumi
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Clin Cancer Res 9:947-54. 2003..These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma... - EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiencyYvette L Kasamon
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Am J Hematol 69:289-93. 2002..EBV-associated lymphoproliferative disease can thus develop in the absence of overt immunodeficiency and may trigger a demyelinating polyneuropathy...